Hours after announcing the close of its $22.50-per-share tender offer for ev3 Inc., Covidien plc announces the consummation of the $2.6 billion buyout of the Minnesota vascular device maker.
Covidien plc (NYSE:COV) consummated a $2.6 billion deal to acquire ev3 Inc. (NSDQ:EVVV), hours after closing its tender offer for shares in the Minnesota vascular device maker.
Mansfield, Mass.-based Covidien shelled out $22.50 per share for about 100.8 million ev3 shares. That $2.27 billion gave it roughly 87.7 percent of ev3's outstanding shares and cleared the way for a Covidien holding company to complete the merger without any further input from ev3 stockholders.
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...